▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3115 by analyst upside · 2026-09-28
SRPT
Sarepta Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+17.1%
implied upside to consensus target
Current Price $18.67
Consensus Target $21.86
Bull Target $38.0
Bear Target $5.0
Analysts Covering 22
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
7
Hold
11
Sell
4
52-Week Low $14.68
52-Week High $25.32
YTD Return -12.4%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E 7.1x
EPS (TTM) $-1.57
PEG Ratio -0.09
Dividend Yield N/A
Revenue (TTM) $2.0B
Profit Margin -6.9%
52-WEEK RANGE
52-Week Low $14.68
52-Week High $25.32
Current Price $18.67
Bear Target $5.0
Bull Target $38.0
● Now $18.67 ● Target $21.86
TRADING DATA
Avg Volume 3.1M
YTD Return -12.4%
Analyst Count 22
Consensus Hold
Upside to Target +17.1%
Last Updated 2026-09-28

ANALYST SUMMARY

Sarepta Therapeutics, Inc. (SRPT) is currently trading at $18.67 with a Wall Street consensus price target of $21.86, implying potential upside of 17.1% over the next 12 months. 22 analysts currently cover SRPT, with a consensus rating of Hold - 32% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $38.0, while the most cautious has a target of $5.0.

SRPT operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 12.4% year-to-date and is currently trading near the lower end of its 52-week range of $14.68 – $25.32.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

LKFT +4.4%
Lakefront Biotherapeutics NV
$2B · P/E 2.9x · Underperform
AUPH +8.6%
Aurinia Pharmaceuticals Inc.
$2B · P/E 7.2x · Buy
MD +0.1%
Pediatrix Medical Group, Inc.
$2B · P/E 12.6x · Hold
HRMY +14.8%
Harmony Biosciences Holdings, Inc.
$2B · P/E 13.4x · Buy
PBH +45.5%
Prestige Consumer Healthcare Inc.
$2B · P/E 13.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SRPT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler - Reiterated
Neutral → Neutral 2026-07-09 14% win rate (7 calls)
Wolfe Research ↑ Upgrade
Peer Perform → Outperform 2026-07-09 Building track record
HC Wainwright & Co. reit
Sell → Sell 2026-04-16 31% win rate (48 calls)
Citigroup - Reiterated
Sell → Sell 2026-03-26 Building track record
Needham reit
Underperform → Underperform 2026-03-26 20% win rate (5 calls)
Oppenheimer reit
Outperform → Outperform 2026-03-19 14% win rate (7 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-03-13 Building track record
Citigroup - Reiterated
Sell → Sell 2026-03-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
26
out of 100
Coverage depth
24/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →